Strs Ohio Has $59.24 Million Stock Position in Gilead Sciences, Inc. $GILD

Strs Ohio increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 534,303 shares of the biopharmaceutical company’s stock after acquiring an additional 22,123 shares during the quarter. Strs Ohio’s holdings in Gilead Sciences were worth $59,238,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences in the fourth quarter valued at about $215,000. Golden State Wealth Management LLC raised its stake in shares of Gilead Sciences by 14.5% during the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 109 shares during the last quarter. Koshinski Asset Management Inc. lifted its stake in Gilead Sciences by 23.8% in the first quarter. Koshinski Asset Management Inc. now owns 4,350 shares of the biopharmaceutical company’s stock valued at $487,000 after buying an additional 836 shares during the period. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences in the first quarter valued at about $25,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. TD Cowen boosted their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a report on Monday, October 20th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Cantor Fitzgerald increased their price target on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.61.

Gilead Sciences Stock Up 0.5%

Shares of GILD stock opened at $118.50 on Thursday. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The firm has a market capitalization of $147.04 billion, a P/E ratio of 23.61, a PEG ratio of 0.81 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm’s fifty day moving average price is $115.51 and its two-hundred day moving average price is $111.43.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the company posted $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.